Thursday, October 15, 2026

83% of Companies Struggle with AI Infrastructure as Cloud Providers See Revenue Opportunity

83% of organizations report their internal teams struggle with AI workloads, while 97% say cloud infrastructure is essential for scaling AI. 65% call their AI environments too complex to manage, driving 72% to rely on third-party expertise.

83% of Companies Struggle with AI Infrastructure as Cloud Providers See Revenue Opportunity
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

83% of organizations say their internal teams struggle with AI workloads, creating a massive opportunity for cloud infrastructure providers. 97% of organizations agree cloud infrastructure is essential to scaling AI.

65% of organizations say their AI environments are too complex to manage internally. 72% now rely on third-party expertise to build and manage their AI infrastructure. More than half cite cloud as their fastest path to production.

Cloud providers are responding. Akamai launched its Inference Cloud service targeting organizations overwhelmed by AI infrastructure complexity. AWS, Google Cloud, and Microsoft Azure have expanded managed AI services throughout 2025.

The data points to a structural shift in enterprise technology spending. Organizations are abandoning attempts to build AI infrastructure in-house. They're choosing managed services and cloud-based AI platforms instead.

This trend should accelerate AI infrastructure-as-a-service revenue growth over the next 12-18 months. Major cloud providers reported double-digit growth in AI infrastructure revenue in Q4 2025. Analysts predict this will accelerate as more organizations hit complexity limits.

The complexity problem stems from several factors. AI workloads require specialized hardware like GPUs and TPUs. They demand different scaling patterns than traditional applications. Organizations need expertise in model deployment, inference optimization, and cost management.

72% relying on third-party expertise represents a significant increase from two years ago. This suggests the skills gap is widening faster than organizations can train internal teams.

For investors, the opportunity is clear. Cloud providers with strong AI infrastructure offerings should capture growing enterprise budgets. Companies offering managed AI services and platforms will benefit from organizations outsourcing complexity.

The 97% consensus on cloud being essential to AI scaling suggests this isn't a temporary trend. Organizations have concluded cloud infrastructure is non-negotiable for AI initiatives. This positions cloud providers for sustained revenue growth from AI workloads.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com